Properly prescribed testosterone replacement therapy, or TRT, is not shown by current evidence to shorten lifespan. TRT is intended to restore testosterone to a physiological range in men with confirmed hypogonadism. It is not the same as bodybuilding steroid use or taking high doses to push testosterone above the normal range.
The largest recent cardiovascular safety trial, the 2023 TRAVERSE trial, studied men aged 45 to 80. Its results did not show an increased risk of major cardiovascular events during roughly three years of follow-up. That does not prove TRT is risk-free or that its safety is established over several decades.
TRT and Lifespan: What the Evidence Shows
| Question | Current answer |
|---|---|
| Does medically supervised TRT shorten life? | No convincing evidence shows that it does. |
| Does TRT extend lifespan? | No. TRT is not established as a longevity treatment. |
| Does TRT increase heart attack or stroke risk? | The largest cardiovascular safety trial found no increase in major cardiovascular events over approximately three years. |
| Are there still important risks? | Yes. Blood pressure increases, pulmonary embolism, atrial fibrillation, acute kidney injury, elevated hematocrit and fertility suppression are important concerns. |
| Is lifelong safety proven? | No. Long-term mortality data remain limited. |
What Did the Largest TRT Safety Trial Find?
TRAVERSE studied men with hypogonadism who were 45 to 80 years old and had existing cardiovascular disease or a high risk of cardiovascular disease.
A major cardiovascular event occurred in:
- 7.0% of men receiving testosterone
- 7.3% of men receiving placebo
The testosterone group did not have a greater risk of the trial's primary cardiovascular outcome. That outcome included cardiovascular death, nonfatal heart attack and nonfatal stroke. Average follow-up lasted approximately 33 months.
The trial did identify several safety signals. Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often in the testosterone group. The results support cardiovascular safety over the period studied, but they do not show that TRT has no risks or that it is safe for every patient indefinitely.
Does TRT Increase Mortality?
Available randomized-trial evidence has not shown increased mortality from TRT. However, most studies recorded too few deaths to provide a definitive answer.
A 2022 individual-patient-data meta-analysis found no increased risk of cardiovascular or cerebrovascular events with testosterone in the short to medium term. The researchers also reported that there were too few deaths to determine TRT's effect on mortality reliably.
A 2024 evidence synthesis of 35 randomized trials involving 5,601 participants found:
- All-cause mortality: 0.4% with TRT versus 0.8% with placebo
- Cardiovascular or cerebrovascular events: 7.5% with TRT versus 7.2% with placebo
The authors said the mortality data were too limited to establish whether TRT reduces, increases or has no effect on lifespan.
TRT has not been shown to shorten lifespan, but it also has not been proven to increase lifespan.
How Can TRT Cause Serious Problems?
TRT can become harmful when testosterone levels rise too high, when an underlying condition is missed or when side effects are not monitored.
1. Elevated Hematocrit
Testosterone can increase red blood cell production. A very high hematocrit can make blood more viscous and raise concern about clotting and cardiovascular complications.
The American Urological Association recommends intervention when hematocrit reaches 54% or higher. Possible responses include adjusting the dose or temporarily stopping treatment.
2. Increased Blood Pressure
The U.S. Food and Drug Administration required testosterone product labels to include information about increased blood pressure. Chronic uncontrolled hypertension can raise the risk of heart attack, stroke, heart failure and kidney disease.
3. Blood Clots and Pulmonary Embolism
Pulmonary embolism and other venous thromboembolic events have been reported in people using testosterone products.
Sudden shortness of breath, chest pain, coughing blood or one-sided leg swelling requires urgent medical attention.
4. Atrial Fibrillation and Fluid Retention
TRAVERSE recorded more atrial fibrillation and acute kidney injury in the testosterone group. Testosterone can also cause fluid retention, which may be more dangerous in people with heart, kidney or liver disease.
5. Fertility Suppression
External testosterone can suppress the brain-to-testicle signals needed for sperm production. TRT may reduce sperm counts or cause azoospermia, meaning no sperm in the semen.
Men who want children soon should discuss alternatives with an endocrinologist or urologist before starting treatment.
Is TRT Safe for Men With Heart Disease?
Cardiovascular disease alone does not establish that TRT is unsafe for every man. In TRAVERSE, men with established or high cardiovascular risk did not experience more major cardiovascular events than men taking placebo during the study period.
Treatment still requires an individual assessment. The Endocrine Society recommends against starting TRT in men with a heart attack or stroke within the previous six months, uncontrolled heart failure, elevated hematocrit or certain other high-risk conditions.
TRT should also be avoided or carefully evaluated in men with:
- Known or suspected prostate cancer
- Breast cancer
- Untreated severe obstructive sleep apnea
- Severe urinary symptoms
- A strong desire to preserve near-term fertility
- Uncontrolled hypertension
- A history of problematic blood clots
Does TRT Shorten Lifespan When Testosterone Is Used for Aging?
TRT is not FDA-approved simply to reverse normal aging, improve appearance or increase athletic performance. The FDA approves testosterone products for men with low testosterone associated with a medical condition, not for general age-related enhancement.
Bodybuilding doses, combinations with other anabolic steroids and unsupervised testosterone use are different from standard TRT. These regimens can produce testosterone levels well above the normal physiological range and have not been tested for safety in the same way as medically supervised replacement therapy. FDA product labeling warns about testosterone abuse at higher-than-recommended doses and when testosterone is combined with other anabolic steroids.
How to Reduce the Risks of TRT
Before starting TRT, a clinician should confirm:
- Symptoms consistent with testosterone deficiency
- Consistently low, accurately measured testosterone levels
- The likely cause of the low testosterone
- Blood pressure and cardiovascular history
- Hemoglobin and hematocrit
- Prostate cancer risk and appropriate PSA monitoring
- Fertility plans
- Possible sleep apnea and other conditions that TRT could worsen
After treatment begins, the Endocrine Society recommends monitoring treatment response, adverse effects and compliance. Its guideline recommends checking hematocrit at baseline, again after three to six months, and then annually.
Bottom Line
For a man considering TRT, the decision should rest on symptoms, repeatedly confirmed low testosterone, the likely cause, fertility plans and baseline health risks. TRT is not a general anti-aging treatment or a performance-enhancing regimen.
Regular monitoring should include blood pressure, hematocrit, testosterone levels and prostate risk. The available evidence is reassuring about major cardiovascular events over roughly three years, but safety over several decades remains uncertain.